Oppenheimer Asset Management’s Abivax ABVX Stock Holding History

Oppenheimer Asset Management’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Sell	4,477 -19	-0.4%	-$2.15K	0.01%	848
2026 Q1	$501K	Buy	4,496 +115	+3%	+$13.6K	0.01%	868
2025 Q4	$591K	Buy	4,381 +1,280	+41%	+$140K	0.01%	781
2025 Q3	$263K	Buy	+3,101	New	+$190K	﹤0.01%	1034

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oppenheimer Asset Management's ABVX Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Abivax (ABVX) stake by 0.42% in Q2 2026, selling an estimated $2.15K and leaving 4,477 shares worth $597K. The position accounts for 0.01% of the portfolio, ranked #848.

Oppenheimer Asset Management first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 304 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Oppenheimer Asset Management held 4,477 shares of Abivax worth $597K as of Q2 2026.
Oppenheimer Asset Management sold 19 Abivax shares in Q2 2026, an estimated $2.15K.
Abivax made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #848 holding.
Oppenheimer Asset Management first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
304 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.